Publikasi Scopus FKUI 2021 per tanggal 31 Mei 2021 (358 artikel)

Khaedir Y., Kartika R.
57210448725;57216548032;
Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19
2021
Journal of Interferon and Cytokine Research
41
2
37
43
Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia; Immunology, Master's Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia; Division of Metabolic, Endocrinology and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia
Khaedir, Y., Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia, Immunology, Master's Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia; Kartika, R., Division of Metabolic, Endocrinology and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been a major threat to global public health. In Indonesia, the cases have rapidly increased, and the case fatality rate remains high. With COVID-19, most of the deaths have been caused by acute respiratory distress syndrome and dysregulation of the immune response. A lung biopsy from a patient with COVID-19 showed inflammatory cellular infiltration with diffuse alveolar damage. Massive pulmonary destruction has also been reported as a result of highly increased levels of proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-1β, interferon-γ(IFN-γ), induced protein 10 (IP-10), and monocyte chemoattractant protein-1 (MCP-1). IL-6 is an inflammatory cytokine produced by various cell types, including immune cells and nonleukocytes, such as endothelial cells, fibroblasts, epithelial cells, type II pneumocytes, and certain tumor cells. Several studies have shown that IL-6 contributes to the severity and mortality of COVID-19. In this review, we would like to explore the immune response in COVID-19 and the role of IL-6 in the immunopathogenesis of COVID-19. © Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
coronavirus disease 2019; immune response; interleukin-6
interleukin 6; tocilizumab; IL6 protein, human; interleukin 6; interleukin 6 receptor; JAK1 protein, human; JAK2 protein, human; Janus kinase 1; Janus kinase 2; Janus kinase inhibitor; monoclonal antibody; pyrazole derivative; ruxolitinib; sarilumab; tocilizumab; cell infiltration; clinical outcome; coronavirus disease 2019; cytokine storm; human; immune response; immunopathogenesis; lung alveolus cell; priority journal; prospective study; Review; Severe acute respiratory syndrome coronavirus 2; signal transduction; cytokine release syndrome; drug effect; immunology; Indonesia; pathology; respiratory distress syndrome; Antibodies, Monoclonal, Humanized; COVID-19; Cytokine Release Syndrome; Humans; Indonesia; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Janus Kinase Inhibitors; Pyrazoles;
Mary Ann Liebert Inc.
10799907
33621130
Review
Q2
799
5928